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In hematologic malignancies, the microenvironment is often characterized by nonneoplastic cells with peculiar phenotypic and
functional features. This is particularly true in Hodgkin’s lymphoma (HL), in which T lymphocytes surrounding Hodgkin’s Reed-
Sternberg cells are essentially polarized towards a memory T-helper type 2 phenotype. In this paper we will ﬁrst evaluate the
main processes modulating T-cell recruitment towards the lymph node microenvironment in HL, especially focusing on the role
played by cytokines. We will then consider the most relevant mechanisms of immune escape exerted by neoplastic cells in order to
evade antitumor immunity. The potential pathogenetic and prognostic impact of regulatory T cells in such a context will be also
described. We will ﬁnally overview some of the strategies of cellular immunotherapy applied in patients with HL.
1. InﬁltratingLymphocytes in
Hodgkin’s Lymphoma
In hematologic malignancies, a speciﬁc pathogenetic role is
often played by nonneoplastic cells within the microenvi-
ronment. This is particularly true in Hodgkin’s lymphoma
(HL), in which T lymphocytes surrounding Hodgkin’s Reed-
Sternberg cells (HRSCs) show peculiar phenotypic and
functionalfeatures.ApossibleimpairmentoftheT-cellcom-
partment has been investigated in HL since the tuberculin
puriﬁed protein derivative (PPD) skin test was found to be
frequently negative in large series of patients, and therefore
a dysregulation involving delayed cellular immune responses
was hypothesized [1]. Although inﬁltrating T lymphocytes
are essentially polarized towards a memory T-helper type 2
(Th2) phenotype [2], several studies have shown possible
diﬀerences among the diﬀerent subtypes of HL. Among the
molecules potentially involved in modulating the pattern of
T-cell inﬁltration, TARC (thymus and activation-regulated
chemokine), a chemokine able to attract activated Th2 cells,
was found on immunohistochemical staining to be highly
expressed in most-classical HL, but not in lymphocyte-
predominant HL and non-Hodgkin lymphomas (NHL).
This diﬀerent expression may at least partially justify the
discrepanciesobservedamongT-cellinﬁltratesindistinctHL
subtypes [3]. Also, the T-cell transcription factor proﬁle was
shown to be consistent with the lymphoid compartment of
origin of the diﬀerent HL subtypes. In particular, in classical
and nodular lymphocyte-predominant HL, the expression
of GATA-3 and T-bet recalls the pattern typical of normal
interfollicular T-cells and normal germinal centers, respec-
tively [4]. Interestingly even the T-cell activation proﬁle
was compared in patients withlymphocyte-predominant HL
with nodular or diﬀuse pattern. By evaluating CD134 and
CD38 expression, it was shown that in the nodular variant,
T cells express markers of transient/early T-cell activation,
whilethediﬀusepatternischaracterizedbypersistentcellular
activation, resembling what was observed in T-cell-rich large
B-cell NHL [5]. More recently, another report focused on
lymphocyte-rich classical HL, showing that this subtype is
characterized by a stronger expression of B-cell transcription
factors in neoplastic cells and by a follicular T-cell back-
ground with features intermediate between the classical and
the nodular lymphocyte-predominant variants [6].
The microarray technology was even able to highlight
the prognostic signiﬁcance of the composition of the T-cell2 Advances in Hematology
inﬁltrate in a cohort of 267 patients. In fact, low numbers
of inﬁltrating CD8+, CD56+, and CD57+ cells and high
n u m b e r so fg r a n z y m eB +a n dT I A - 1 +c e l l sw e r ea s s o c i a t e d
with a signiﬁcantly worse outcome, as outlined by a higher
frequency of leukocytosis, B symptoms, advanced clinical
stage, and by lower response rates [7].
In order to shed some light on the mechanisms
determining the composition of this microenvironment,
the expression and function of T-cell homing molecules
were speciﬁcally evaluated. Chemokine receptors: CXCR3,
CXCR4, and CCR7 and adhesion molecules including CD62
ligand were found to be expressed on most T-cells within
HL tissues, while the corresponding ligands were expressed
on malignant cells and vascular endothelium. These features
resemble the mechanisms of T cell recruitment observed
in normal lymph nodes, thus further highlighting the cross
talk among neoplastic and nonneoplastic cells within the HL
microenvironment [8].
The issue of the clonality of inﬁltrating T lymphocytes
was also assessed in two diﬀerent studies. In the ﬁrst one,
CD8+ T cells were shown to be a polyclonal population with
limited clonal expansion. In fact, although sequence analysis
oftheVregionsrevealedthepresenceofCD8+expansionsin
all cases, most of these clonal expansions accounted for less
than 10% of the whole CD8+ T cell population. Moreover,
a comparison of the V region sequences did not provide
evidence that CD8+ T-cells were driven towards a common
antigen[9].Inthesecondstudy,theTcellsadherenttoHRSC
were examined by single-cell analysis for the T cell receptor
(TCR) gamma gene in 5 HL patients. While no evidence of
a clonal expansion was obtained in four of ﬁve patients with
classicHL,clonalTCRgammasequencesweredetectedinthe
only patient with lymphocyte-predominant HL, suggesting
that even in HL patients, neoplastic cells may sometimes act
as antigen-presenting cells [10].
A gene expression proﬁle analysis was performed also
on peripheral CD3+ T cells isolated from untreated patients
with HL, showing that this cell subset seems to be involved in
a Th1 immune response even in peripheral blood. However,
this cell subpopulation, hypothetically supporting the anti-
tumor immunity, appears to be functionally impaired, as
shown by the balance in the expression of genes modulating
either the cell cycle or the immune response [11].
2. CytokineProductioninthe Hodgkin’s
Lymphoma Microenvironment
The release of cytokines within the lymph node microenvi-
ronment has been often advocated as possible mediator in
the crosstalk among HL neoplastic cells and inﬁltrating T-
cells. The overall pattern of cytokine gene expression has
been shown to be similar in classic HL and reactive lymph
nodes, as regards IL-2, IL-4, IL-5, and interferon (IFN)-
gamma [12]. On the other side, it is known that HRSC
can bind T lymphocytes in an antigen-independent way,
based on LFA-3 (lymphocyte function-associated antigen 3)
to CD2 and ICAM-1 (intercellular adhesion molecule 1) to
LFA-1 interactions. Moreover, they show unusually strong
expression of the costimulatory molecules CD80 and CD86,
whose ligand CD28 is expressed on T-cells [13]. HRSC
cells are also known to produce interleukin-(IL-) 1a, TNF-
alpha, IL-6, IL-7, IL-9, IL-10, IL-13, and tumor growth
factor-(TGF-) beta [14], the latter being characterized by a
prominent role in suppressing T-cell responses [15].
More recently, the expression of potentially relevant
chemokines and chemokine receptors was studied in lymph
nodes from 24 patients with HL and in 5 control lymph
nodes by combining in situ hybridization, immunohis-
tochemistry, and ﬂow cytometry. Among the diﬀerent
cytokines tested, RANTES was expressed almost exclusively
by T cells. Among receptors, CCR3 and CCR5 were highly
expressed in T cells—the former in both CD4+ and CD8+
cells,whilethelattermainlyinCD4+cells.However,allthese
chemokines and receptors were not detected on neoplastic
cells. This preferential distribution seems to suggest a
potential but yet not completely explained involvement of
these molecules in the leukocyte recruitment towards the HL
lymph node [16]. The relationship between the expression
on neoplastic cells of some speciﬁc CXC and CC chemokines
suchasMIG,IP10, andTARC andthe inﬁltration ofTh1and
Th2 lymphocytes was evaluated in another study, showing
that all these chemokines may inﬂuence the Th2 polarization
typical of HL [17].
Similarly, several interleukins with the relative receptors
have been shown to play a role in the interaction among
neoplastic and inﬁltrating cells. After the detection of the
IL-3 receptor (IL-3R) on HRSC, it has been hypothesized
that these neoplastic cells could be able to increase the
production of IL-3 by preactivated T cells, thus suggesting
an involvement of IL-3/IL-3R interactions in the neoplastic
proliferation through a paracrine mechanism [18]. More-
over, both HL-derived cell lines and primary HRSC from
lymph node tissues of HL patients express the IL-7 receptor.
As these cell lines show the constitutive production of IL-
7 and neutralizing anti-IL-7 antibodies induce a relevant
inhibition of their basal proliferation, IL-7 seems to be also
involved in autocrine circuitries modulating neoplastic cell
growth. Moreover, the IL-7/IL-7R axis appears to act as
a cofactor for the expansion of regulatory T-cells (Treg)
and as a potential enhancer for the microenvironmental
productionofIL-6,acytokineassociatedwiththepresenceof
“B” symptoms and poor outcome in HL [19]. Interestingly,
in HL patients, also peripheral T lymphocytes have been
shown to display an atypical proﬁle of cytokine production,
characterized by reduced intracellular IL-2, TNF-alpha, and
IFN-gamma and increased cytoplasmic IL-4 production,
beingtheCD3+CD8+subpopulationspeciﬁcallyresponsible
for the increased levels of IL-4 [20, 21].
3. Mechanismsof ImmuneEscapeby
Neoplastic Cells
Considering that neoplastic cells are able to proliferate
in HL although their microenvironment is characterized
by an extensive inﬂammatory inﬁltrate, the mechanisms
of immune escape have been deeply investigated in thisAdvances in Hematology 3
disorder. For instance, one of the potentially involved
molecules is the immunoregulatory glycan-binding protein
galectin-1 (Gal1) which has been shown to be selectively
overexpressed on HRSC. In fact, blockade of Gal1 was able
to restore the Th1/Th2 balance which is usually inverted
in HL, whereas treatment of activated T-cells with Gal1
favored the secretion of Th2 cytokines and the expansion
of CD4+CD25 high forkhead box P3 (FOXP3)+ Treg. This
ﬁndingthereforeimpliesthatGal1isinvolvedinthedevelop-
ment and maintenance of an immunosuppressive Th2/Treg-
skewed microenvironment [22] .T h er o l eo ft h i sm o l e c u l e
was also examined in the context of Epstein-Barr virus-
(EBV-) speciﬁc CD8+ T-cell responses in HL. Its expression
was associated with a reduced CD8+ T-cell inﬁltration and
more speciﬁcally with an impaired response towards latent
membrane proteins (LMP) 1 and 2. Moreover, the in vitro
exposure to recombinant Gal-1 inhibited proliferation and
interferon-gamma expression by EBV-speciﬁc T cells [23].
Also the possible role played by the PD-1 (programmed
death-1) protein was explored. In fact, this molecule and
its ligand are thought to be involved in the functional
impairment of T cells in chronic viral infections or tumor
immune evasion. HL and T cell NHL, but not B-cell NHL,
were shown to overexpress PD-1 ligand, while PD-1 was
markedly elevated in tumor-inﬁltrating and peripheral T
cells of HL patients. Moreover, blockade of the PD-1 system
was able to restore the IFN-gamma production by HL-
inﬁltrating T cells [24]. Using a genome-wide transcriptional
approach, CD4+ T cells in HL but not in follicular NHL
were demonstrated to be under the inhibitory inﬂuence
of both TGF-beta and PD-1 in vivo [25]. An increase in
the number of PD-1+ lymphocytes, measured within a
tissue microarray platform, was also shown to be a stage-
independent negative prognostic factor of overall survival
as opposed to the number of FOXP3+ Treg [26]. All these
ﬁndings seem to suggest that the impairment of the cellular
immunity typical of HL can mirror a T cell exhaustion,
which is at least partially mediated by the PD-1 signaling
pathway.
It is worth noting that very recently an increased number
of tumor-associated macrophages was shown by gene-
expression proﬁling to be signiﬁcantly associated with pri-
mary treatment failure, shortened progression-free survival,
increased likelihood of relapse after autologous hematopoi-
etic stem cell transplantation, and shortened disease-speciﬁc
survival in a large cohort of HL patients [27].
Several other molecules have been tested for their
possible involvement in such a context. For instance,
Prostaglandin E2 has been shown to impair CD4+ T-cell
activationbyinterferingwiththemechanismsofintracellular
transduction downstream TCR and CD28 [28]. Another
possible mechanism of T-cell activation impairment was
identiﬁed in the reduced expression by HRSC of the B7 pro-
teins [29]. Tissue inhibitor of metalloproteinases 1 (TIMP-
1) is a protein with proteinase-inhibiting and cytokine
properties which has been advocated not only as a survival
factor for HRSC but, even more importantly, as potential
immunosuppressive agent. In fact, in situ hybridization
showed TIMP-1 RNA expression on HRSC, while TIMP-1
productionbyHRSCcellswasdemonstratedonimmunohis-
tochemical analysis. TIMP-1 was also shown to inhibit T cell
cytotoxicity both against autologous cells presenting tumor-
associated antigens and within allogeneic mixed lymphocyte
cultures [30]. Also, the downregulatory molecule cytotoxic
T lymphocyte-associated antigen 4 (CTLA-4) was shown to
play a possible role, as the proportion of CTLA-4+/CD3+
cells negatively correlated with proliferative activity, IL-2 and
IFN-gamma production by T lymphocytes in HL patients
[31]. Even CD30, which is typically expressed on HRSC, was
shown to inhibit T cell proliferation. More speciﬁcally, anti-
CD3-stimulated T cells in the presence of CD30 failed to
increase tritium uptake, to express CD25 and CD26 and to
produceIL-2.Thiseﬀectwashowever,reversedafteraddition
of exogenous IL-2 or pretreatment of HRSC with anti-CD30
[32]. Interestingly, also the intracellular serpin proteinase
inhibitor 9 (PI9) was found to be expressed in 10% of HL
patients. This protein is the only known inhibitor of the
proteolytic activity of granzyme B, the primary mediator
of apoptosis induced by cytotoxic T lymphocytes and
natural killer (NK) cells, thus suggesting another possible
mechanism by which neoplastic cells could interfere with
antitumor immunity in HL [33]. At least in other subtypes
of lymphoma indoleamine 2,3-dioxygenase has been shown
to be speciﬁcally, involved in the mechanisms of tumor
resistance to chemoimmunotherapeutic treatments, likely
due to an abnormally increased stimulation of tryptophan
catabolism and to the consequent inhibition of antitumor
immunity [34, 35].
4. Role of Regulatory T Cells
Treg represent a small fraction of peripheral CD4+ T cells
which plays a crucial role in the maintenance of immune
tolerance [36]. More speciﬁcally, they have been shown
to inﬂuence the susceptibility to and the evolution of
infective, neoplastic, and autoimmune diseases [37–39]. The
possible involvement of T cells with immunomodulatory
properties in HL pathogenesis was ﬁrstly hypothesized in
2004.InﬁltratingTcellswereshowntobeanergictodiﬀerent
kindsofstimulationandtosuppressperipheralmononuclear
cells when cocultured. Furthermore, ﬂow cytometry demon-
stratedahighfrequencyofbothIL-10andCD4+CD25+Treg
secretion in the lymph nodes of HL patients. Interestingly,
their suppressive function was abrogated by IL-10 neutral-
ization, prevention of cell-to-cell contactade and block of
CTLA-4 [40]. One year later, some studies ﬁrstly suggested
a possible positive prognostic impact for Treg in patients
with HL. Expression of granzyme B, TIA-1, and FOXP3 was
evaluated by immunohistochemistry in tissue microarrays
of 257 patients, showing that low inﬁltration of Treg in
association with high inﬁltration of cytotoxic T cells could
predict an unfavorable outcome [41]. Similarly, a reduced
FoxP3/granzyme B+ ratio was shown to predict poor failure
free survival [42] .T h ea b s o l u t en u m b e ro fi n t r a t u m o r a l
FOXP3+ cells studied by immunohistochemistry on tissue
microarrays was of independent prognostic signiﬁcance for
failure-free survival and of borderline signiﬁcance for overall
survival in classical HL [43]. All these ﬁndings, based on4 Advances in Hematology
samples taken at diagnosis, were conﬁrmed also in a cohort
of patients with refractory or relapsed disease [44]. Only one
study had results not in line with the above-mentioned data,
showing that a high ratio of Treg over Th2 cells may result
in a signiﬁcantly shortened disease-free survival, therefore
implying a possible inhibitory eﬀect performed by Treg on
antitumor immune responses [45].
Several mechanisms have been considered as possible
mediators of Treg recruitment towards the HL microenvi-
ronment. For instance, the inhibition of CCR4 by using
a chimeric anti-CCR4 monoclonal antibody was shown
to deplete CCR4+ T cells and to inhibit the migration
of CD4+CD25+ T cells in vitro [46]. Also, the aberrant
expression of IL-21, apart from regulating STAT3 signaling
and protecting HRSC from apoptosis, was demonstrated
to attract Treg via regulation of macrophage-inﬂammatory
protein-3alpha MIP-3alpha in HRSC [47]. The EBV infec-
tion was similarly considered as a potential mediator of
Treg recruitment. In fact, the expression of the EBV nuclear
antigen 1 in HRSC was shown to mediate the upregulation
of the chemokine CCL20 and consequently the migration of
Treg [48]. On the other side, some data seem to suggest that
the expression of LAG-3 by tumor-inﬁltrating lymphocytes
with regulatory properties could impair the anti-EBV CD8+
immune reaction in HL patients [49]. In another study,
KM-H2, which was established as an HRSC line, was
demonstrated to promote a bidirectional diﬀerentiation of
CD4+ naive T cells toward Foxp3+ T-cells and CD4+
cytotoxic lymphocytes, suggesting that neoplastic cells may
act within the HL microenvironment as antigen-presenting
cells driving the diﬀerentiation of T helper cells [50].
The enrichment of Treg among inﬁltrating lymphocytes
has been even suggested as a possible diagnostic marker,
useful in distinguishing classical HL from other entities
[51]. Increased frequencies of CD4+CD25+ Treg have also
been demonstrated on peripheral blood of patients with
HL [52]. More recently, apart from CD4+CD25+FoxP3+
Treg, other subfamilies of cells with immunomodulatory
properties, such as CD4+CD26− T cells, have been sug-
gested to potentially exert immunomodulatory functions
within the lymph node microenvironment of patients with
HL [53].
5. Strategies of Cellular Immunotherapy
Over the last few years, several studies have tried to establish
if the biological impact that T lymphocytes have on HL
pathogenesiscouldbetranslatedintopotentialimmunother-
apeutic strategies. The demonstration, even in HL patients,
ofagraft-versus-lymphomaeﬀectinthecontextofallogeneic
hematopoietic stem cell transplantation and donor lympho-
cyte infusions [54], represents the ideal platform for such an
approach. In order to overcome the apparent impairment of
theantitumorimmunitytypicalofHL,diﬀerentmechanisms
have been investigated.
In particular, several laboratory studies have addressed
the defective interaction among HRSC and T cells observed
in course of HL. For instance, it is well known that HRSC
preferentially attract Th2 T cells and Treg, therefore gen-
erating an immunosuppressed tumor environment. On the
other side, CD8+ T cells lack CCR4 and are nonresponsive
to chemokines usually expressed on HRSC. In this regard it
was shown that a potential approach to make CD8+ T cells
able to eﬃciently migrate towards HRSC was the induced
expression of CCR4. Moreover, the concomitant expression
of both CCR4 and of an anti-CD30 chimeric antigen
receptor even allowed them to enhance tumor control when
infused intravenously in mice engrafted with human HL
[55]. Another potentially reversible feature of HRSC is the
resistance to CD8+-mediated killing via granzyme B, at least
partially due to defects in mitochondrial apoptotic pathways
and elevated XIAP (X-linked inhibitor of apoptosis protein)
expression. In fact, the expression of the proapoptotic factor
Smac and the downregulation of XIAP by RNA interference
were demonstrated to enhance the apoptotic response of
HRSC as well as their susceptibility to CD8+ cytotoxicity
[56]. Also, the stimulation of the zeta chain expression has
been explored as potential immunotherapeutic approach in
an in vitro study, as HL patients express on their peripheral
T and NK cells reduced levels of this key molecule in TCR
activation [57].
Another strategydesigned torevertthefunctionalanergy
of T cells surrounding HRSC was based on a fusion protein
represented by an anti-CD30 antibody targeting also IL-
2, or IL-12. After binding to CD30+ HL cells, anti-CD30-
IL-2 or anti-CD30-IL-12, antibody-cytokine fusion proteins
were able to induce resting NK cells, but not T cells,
to lyse the lymphoma cells with very high eﬃciency [58,
59]. Moreover, as TGF-beta secretion is able to inhibit
tumor-speciﬁc cellular immunity, cytotoxic T lymphocytes
have been engineered with a dominant negative TGF-beta
receptor in order to resist the antiproliferative eﬀects exerted
b yt h i sm o l e c u l eb o t hin vitro and in vivo [60–62].
A very interesting point of view has been also oﬀered
by studies focusing on the role of the so-called side-
population, constituted by progenitor cells within the
neoplastic population with increased resistance to radiation
and chemotherapy. It was shown that both HL cell lines
and primary HL tumor samples contain a distinct side cell
population, showing increased resistance to gemcitabine but
also expressing higher levels of tumor-associated antigens,
which could be potentially recognized and killed by speciﬁc
cytotoxicTlymphocytes[63].Itisworthnotingthateventhe
pharmacologic eﬀect of histone deacetylase inhibitors in HL
maybeassociatedwiththeinductionofanantitumoractivity
and with a modulation of the cytokine and chemokine
secretion within the lymph node microenvironment
[64].
Lastly, cytokine-induced killer cells, that is, peripheral
blood mononuclear cells expanded in the presence of IFN-
gamma, IL-2, and a monoclonal antibody against CD3- have
been infused in 7 patients with relapsed HL, showing some
limited responses in few of them. Interestingly, these cells
share functional and phenotypic properties with both T
cells and NK cells and exhibit nonhuman leukocyte antigen
(HLA-) restricted killing of tumor cell targets both in vitro
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6. EBV Antigens asPotentialTargets of
Cytotoxic T Cells
Several studies have highlighted the pathogenetic role of
the EBV infection in HL pathogenesis, thus implying that
immunotherapeutic approaches could potentially rely on
cytotoxic T-cells speciﬁcally directed towards EBV antigens.
Interestingly, EBV expression seems to inﬂuence the compo-
sition of the inﬁltrating lymphocyte population, which on
the other side may have an impact on clinical presentation
and outcome [66].
As it is known that HLA class I molecules present viral
peptides for recognition by CD8+ T cells and that this
T cell subset plays a pivotal role in the control of EBV
infection [67], several studies have focused on the possible
impact on HL pathogenesis of the HLA-mediated EBV
antigen presentation. Very interestingly, segments within the
HLA class I locus have been demonstrated to be speciﬁ-
cally associated with the susceptibility to EBV-positive HL,
therefore suggesting that the antigenic presentation of EBV-
derived peptides is somehow involved in the development
of HL [68]. In another study by logistic regression, HLA-
A∗01 alleles were shown to be associated with increased and
HLA-A∗02 alleles with decreased risk of EBV-related HL.
These allele-speciﬁc associations correspond to nearly 10-
fold variation in the risk of HL between HLA-A∗01 and
HLA-A∗02 homozygotes, pointing once again at the critical
role of cytotoxic T-cell responses in EBV-related HL [69].
Interestingly, in the only case of spontaneous remission
ever reported in HL, a speciﬁc impairment of the anti-
EBV immunity was described at relapse [70]. The cytotoxic
response to EBV latent antigens has been speciﬁcally char-
acterized in both blood and tumor-inﬁltrating lymphocytes
of HL patients. Actually EBV-speciﬁc CD8+ T cells were
detected in blood and biopsy samples from both EBV-
negative and EBV-positive patients. However, EBV-speciﬁc
cytotoxic T-lymphocyte precursors were very rare in the
blood of HL patients or even undetectable at the tumor site,
further suggesting a possible impairment of the immune
responses against EBV [71]. The existence of anti-EBV
cytotoxic T cell responses in patients with EBV-negative HL
was also conﬁrmed in another study addressing the dynamic
variance of this cell population during treatment [72].
The ﬁrst relevant steps in the clinical setting were made
in 2002 when EBV-speciﬁc cytotoxic T-lymphocytes were
ex vivo generated in 13 patients with relapsed HL, by
using autologous EBV-transformed B cells as stimulator
cells. The infusion of these cytotoxic T-lymphocytes was
followed by an increase in EBV-speciﬁc immunity, a decrease
in virus load, homing and persistence of CD8+ T cells to
sites of malignancy, resolution of constitutional symptoms,
and some degree of tumor responses [73–75]. Even better
results were obtained by exploiting genetically modiﬁed
APCs in order to augment the expression and immuno-
genicity of LMP2 and, therefore, the frequency of LMP2-
speciﬁc cytotoxic T lymphocytes [76]. Very interestingly,
also allogeneic anti-EBV cytotoxic T cells have been applied
in such a context, showing a good safety proﬁle and once
again some clinical responses [77]. Local delivery of IL-12 to
tumor sites, by using EBV-speciﬁc T cells transduced with a
retroviral vector expressing the p40 and p35 subunits of this
cytokine, was explored as a possible strategy to overcome the
inhibitory eﬀects of the HL microenvironment on cytotoxic
Tl y m p h o c y t e s[ 78].
As patients with active disease display a functional
impairment of Ag-speciﬁc CD8+ T cells, some studies
have focused on an improved targeting of these CD8+ T
cells towards viral antigens expressed in HL. One of these
strategies was based on the development of an adenoviral
antigen presentation system able to reverse the functional
T cell impairment and restore both IFN-gamma production
and cytolytic function. With this approach, activated CD8+
T cells became able to respond to tumor cells and showed
phenotypic features consistent with those of eﬀector T cells
[79]. One of the limits of immunotherapeutic approaches
targeting EBV antigens is that a subset of malignant cells in
the tumor may lack or lose the expression of these potential
targets. EBV-speciﬁc cytotoxic T lymphocytes expressing
a chimeric antigen receptor speciﬁc for CD30 have been
designed in order to overcome this problem. These cells,
generated from healthy donors and HL patients, were able to
kill both EBV-positive and -negative cells and, in a xenograft
model, produced antitumor eﬀects against EBV−/CD30+
tumors [80].
7.FuturePerspectives
Although HL is considered as one of the most curable
hematologic malignancies, some relevant issues are yet to
be resolved. Firstly, the prognosis of patients which poorly
respond to or relapse after ﬁrst-line treatments is still
unsatisfactory. Moreover, identifying therapeutic approaches
withminimaltoxicitystilllooksessentialinadisorderusually
occurring in young adults. Studies further addressing the
functional features of the T cell immune system in HL
patients could not only oﬀer a deeper understanding of the
biology of this disease but, much more importantly, help
to design new targeted immunotherapeutic strategies with
increased speciﬁcity and therefore improved eﬃcacy and
toxicity proﬁle.
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